Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Documenting functional mobility loss for hypophosphatasia disability approvals requires objective, repeatable evidence rather than symptom descriptions alone. Several key elements strengthen a claim, and important details appear below.
Start with measurable functional testing: 6-minute walk test distances, timed up-and-go results, gait speed, grip strength, and range-of-motion measurements recorded across multiple visits to show decline or persistence. Pair these with imaging and lab documentation, including radiographs showing pseudofractures, stress fractures, osteomalacia, or nonunion, plus low alkaline phosphatase levels and elevated substrates such as PLP, PPi, and PEA, along with any ALPL genetic testing results. Physical and occupational therapy notes carry significant weight when they describe specific activity limitations, assistive device needs, fall history, fatigue onset times, and the duration a person can stand, walk, sit, or lift before pain forces a stop.
Add treating specialist statements that connect diagnosis to work-related restrictions in functional terms, such as inability to sustain walking beyond a set distance or need for unscheduled rest breaks. Keep a daily symptom and activity log covering pain levels, mobility aid use, missed work days, and tasks requiring assistance, since consistency across records matters more than any single test result.
If mobility changes, unexplained fractures, chronic bone pain, or worsening fatigue are affecting daily function, a free, instant, online symptom check can help organize what you are experiencing into clear, shareable language before your next appointment. Understanding patterns in your symptoms early makes documentation stronger and conversations with specialists more productive.
Last reviewed for medical accuracy: 08/18/2026Documenting functional mobility loss for hypophosphatasia disability claims depends on objective, repeatable evidence rather than symptom descriptions alone. Strong claims combine measurable functional testing (6-minute walk test, timed up-and-go, gait speed, grip strength, range of motion) recorded across multiple visits with imaging and labs showing pseudofractures, nonunion, or osteomalacia, low alkaline phosphatase, elevated PLP, PPi, and PEA, and ALPL genetic results. Physical and occupational therapy notes, treating specialist statements tied to work restrictions, and a daily symptom and activity log add critical weight, since consistency across records outweighs any single test. There are several factors that determine whether a claim is approved or denied, and the specific documentation details are explained below.
If mobility changes, unexplained fractures, chronic bone pain, or worsening fatigue are affecting your daily function, a free, instant, online symptom check can translate what you are experiencing into clear, shareable language that strengthens your records before your next appointment.
Last reviewed for medical accuracy: 08/18/2026
When you apply for disability benefits for Hypophosphatasia (HPP), solid documentation of your functional mobility loss is critical. HPP can cause bone pain, muscle weakness, stress fractures, and other symptoms that severely limit daily activities. This guide helps you gather and present the right information to strengthen your Hypophosphatasia disability benefits application.
Social Security and other disability programs assess:
You need to show both medical evidence (lab results, imaging, specialist notes) and functional evidence (how you move, what you can’t do).
Confirm Diagnosis and Disease Severity
Include Imaging and Lab Data
Obtain Specialist and Therapy Reports
A daily log paints a vivid picture of your limitations. Use simple tables or bullet lists to record:
Example entry:
• 8:00 AM – Out of bed: took 10 minutes to sit up and stabilize legs (pain 6/10)
• 8:30 AM – Walked 40 feet to kitchen with cane; rested for 5 minutes (pain 7/10)
• 12:00 PM – Afternoon walk: 20 feet to living room, used walker, needed two 10-minute breaks
Show how HPP affects everyday tasks:
Use bullet points in your statement or function report:
Family members, friends, caregivers, or home health aides can offer objective observations:
A simple “Friend’s Statement” form is available from the SSA website; have them fill it out and sign it.
Including results from recognized mobility tests gives weight to your claim:
Ask your physical therapist to perform these tests, include the scores in your records, and explain what they mean for your daily function.
When you complete your Disability Report (Form SSA-3368 or similar), use concise, consistent language:
Example:
“On most days, I can only walk 70–80 feet before severe thigh pain (8/10) forces me to sit. I use a cane for safety, and I rest for 10–15 minutes before resuming.”
Keep all providers informed that you’re applying for disability:
Disability reviewers look for consistency. If there are gaps in your records:
Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you record fluctuations in pain, mobility, and other HPP-related issues. Try it here.
If your initial claim is denied:
Before submitting your Hypophosphatasia disability benefits application, ensure you have:
Talk to your doctor about any serious or life-threatening issues you’re experiencing. Proper medical oversight is crucial for both your health and your application’s success. Good documentation not only helps secure benefits but also ensures your care team fully understands how Hypophosphatasia affects your daily life.
(References)
* Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Dahir KM, Nunes ME. Hypophosphatasia. 1993. PMID: 20301329.
* Stockler S, Plecko B, Gospe SM Jr, Coulter-Mackie M, Connolly M, van Karnebeek C, Mercimek-Mahmutoglu S, Hartmann H, Scharer G, Struijs E, Tein I, Jakobs C, Clayton P, Van Hove JL. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab. 2011 Sep-Oct;104(1-2):48-60. doi: 10.1016/j.ymgme.2011.05.014. Epub 2011 May 24. PMID: 21704546.
* Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:380-8. PMID: 23858621.
* Faruqi T, Dhawan N, Bahl J, Gupta V, Vohra S, Tu K, Abdelmagid SM. Molecular, phenotypic aspects and therapeutic horizons of rare genetic bone disorders. Biomed Res Int. 2014;2014:670842. doi: 10.1155/2014/670842. Epub 2014 Oct 22. PMID: 25530967; PMCID: PMC4230237.
* Conti F, Ciullini L, Pugliese G. Hypophosphatasia: clinical manifestation and burden of disease in adult patients. Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):230-234. doi: 10.11138/ccmbm/2017.14.1.230. Epub 2017 Oct 25. PMID: 29263739; PMCID: PMC5726215.
* Kishnani PS, Rockman-Greenberg C, Rauch F, Bhatti MT, Moseley S, Denker AE, Watsky E, Whyte MP. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019 Apr;121:149-162. doi: 10.1016/j.bone.2018.12.011. Epub 2018 Dec 18. PMID: 30576866.
* Dahir KM, Seefried L, Kishnani PS, Petryk A, Högler W, Linglart A, Martos-Moreno GÁ, Ozono K, Fang S, Rockman-Greenberg C. Clinical profiles of treated and untreated adults with hypophosphatasia in the Global HPP Registry. Orphanet J Rare Dis. 2022 Jul 19;17(1):277. doi: 10.1186/s13023-022-02393-8. Epub 2022 Jul 19. PMID: 35854311; PMCID: PMC9295501.
* Dahir KM, Kishnani PS, Martos-Moreno GÁ, Linglart A, Petryk A, Rockman-Greenberg C, Martel SE, Ozono K, Högler W, Seefried L. Impact of muscular symptoms and/or pain on disease characteristics, disability, and quality of life in adult patients with hypophosphatasia: A cross-sectional analysis from the Global HPP Registry. Front Endocrinol (Lausanne). 2023;14:1138599. doi: 10.3389/fendo.2023.1138599. Epub 2023 Mar 27. PMID: 37051203; PMCID: PMC10083387.
* Khan AA, Rush ET, Wakeford C, Staub D, Brandi ML. Key Learnings from Clinical Research and Real-World Evidence on Asfotase Alfa Effectiveness in Hypophosphatasia: 10 Years Post-Approval. Adv Ther. 2025 Sep;42(9):4270-4299. doi: 10.1007/s12325-025-03309-1. Epub 2025 Jul 25. PMID: 40715944; PMCID: PMC12394269.
* Kishnani PS, Ing S, Hoover-Fong J, Pallais JC, Voskopoja A, Fang S, Mowrey WR, Rush E, Dahir K. Burden of disease in US patients with skeletal versus muscular or pain manifestations of hypophosphatasia: An analysis from the Global HPP Registry. Bone. 2026 Oct;211:117996. doi: 10.1016/j.bone.2026.117996. Epub 2026 Jun 28. PMID: 42365936.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.